Biomarkers and Early Detection Strategies of Ovarian Tumors

Dear Colleagues,

I am pleased to announce a new Special Issue entitled “Biomarkers and Early Detection Strategies of Ovarian Tumors”, and we wish to to offer authors the opportunity to publish review and original articles related to this scientifically interesting and clinically relevant topic.

Despite the development of new therapies and a better understanding of its biology, ovarian carcinoma (OvCa) remains the leading cause of death in women diagnosed with female genital tract cancers. The American Cancer Society estimates that in 2024, about 19,680 new cases of ovarian cancer will be diagnosed and 12,740 women will die of ovarian cancer in the United States. In other countries, especially those in which cancer prevention, screening, and diagnosis are less developed, the mortality rates due to this malignancy are even higher. This extremely unfavorable outcome of OvCa is mainly caused by the problems with its early detection, when the disease is curable. Apart from OvCa, borderline ovarian tumors (BOTs), considered an intermediate stage between benign tumors and OvCa, also constitute a serious medical problem. BOTs are relatively rare compared to ovarian cancer, but, in contrast to most OvCa, they usually occur in women of reproductive age. Furthermore, some of them may recur, usually as BOTs but sometimes as OvCas.

Considering these facts, the identification of new molecular biomarkers that make qualitative or quantitative alterations to BOTs and OvCas in genomes, methylomes, transcriptomes, proteomes, or metabolomes is of paramount importance in the fight againast these neoplasms. Hopefully, the results of your research studies, when presented in this Special Issue, will provide a groundwork for the development of novel, more effective, and less aggravating methods for ovarian tumor detection, diagnosis, and treatment.

Dr. Lukasz M. Szafron
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• biomarker
• ovarian cancer
• borderline ovarian tumor
• genetic variant
• epigenetics
• transciptomics
• proteomics
• metabolomics
• ovarian tumor prevention
• ovarian tumor treatment